missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Human IL-33 Antibody, R&D Systems™
Goat Polyclonal Antibody has been used in 16 publications
Marca: R&D Systems AF3625
Les retours ne sont pas autorisés pour ce produit.
Consulta la politica di reso
Descrizione
IL-33 Polyclonal specifically detects IL-33 in Human samples. It is validated for Western Blot, Immunohistochemistry, Neutralization, Immunocytochemistry, Dual RNAscope ISH-IHC, ELISA Capture (Matched Antibody Pair).
Specifica
| IL-33 | |
| Polyclonal | |
| Unconjugated | |
| O95760 | |
| IL33 | |
| E. coli-derived recombinant human IL-33 Ser112-Thr270 Accession # O95760 | |
| 100 μg | |
| Primary | |
| Detects human IL-33 in ELISAs and Western blots. In sandwich ELISAs, less than 0.05% cross-reactivity with recombinant mouse (rm) IL-33 is observed. | |
| Human | |
| IgG |
| Western Blot, Immunohistochemistry, Neutralization, Immunocytochemistry, In Situ Hybridization (ISH), ELISA | |
| LYOPH | |
| Western Blot 0.1 ug/mL, Immunohistochemistry 5-15 ug/mL, Neutralization 0.75-3.0 ug/mL, Immunocytochemistry 5-15 ug/mL, Dual RNAscope ISH-IHC 3-25 ug/mL, ELISA Capture (Matched Antibody Pair) 0.2-0.8 ug/mL | |
| C9orf26, C9orf26chromosome 9 open reading frame 26 (NF-HEV), DKFZp586H0523, DVS27, DVS27-related protein, IL1F11, IL-1F11, IL33, IL-33, interleukin 33, Interleukin-1 family member 11, interleukin-33, NFHEV, NF-HEV, NF-HEVNFEHEV, Nuclear factor from high endothelial venules, RP11-575C20.2 | |
| Goat | |
| Affinity Purified | |
| RUO | |
| 90865 | |
| Reconstitute at 0.2 mg/mL in sterile PBS. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. |
Correzione del contenuto del prodotto
Fornite il vostro feedback sul contenuto del prodotto compilando il modulo sottostante.
Titolo del prodotto
Individuate un'opportunità di miglioramento?Condividi una correzione di contenuto